Drug Discovery & Pharmaceuticals

RSS

Atypical antibody shows extremely potent zika-resistant activity

A group of researchers led by Weill Cornell Medicine, New York-Presbyterian, and National Institutes of Health (NIH) investigators has discovered an unusual type of antibody that, even at extremely low concentrations, neutralizes the Zika virus and renders the virus infection undetectable in preclinical models.

22 Nov 2022

The Native Antigen Company introduces new range of influenza antigens

The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest range of influenza antigens for the southern hemisphere’s 2023 flu season.

From The Native Antigen Company 21 Nov 2022

IBS team uncovers new antiviral compounds derived from two Korean native plants

Codonopsis lanceolata, more commonly referred to as "deodeok", is used as a medicinal herb in South Korea.

14 Nov 2022

Understanding immune cell function to improve vaccine efficacy

The immune system’s capacity to remember defeated disease-causing germs and avoid recurrent infections is still poorly understood, but a new study published in Science Immunology fills in some gaps.

From Rutgers University 8 Nov 2022

The Native Antigen Company expands its range of Omicron antigens to include BA.5 variant

The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest SARS-CoV-2 antigens for the newly designated Omicron BA.5 variant.

From The Native Antigen Company 7 Nov 2022

Georgia Tech researchers develop a new biomaterial that could cure Type 1 diabetes

Insulin injections to treat Type 1 diabetes could become a thing of the past, but finding the cure faces many challenges.

4 Nov 2022

Novel liposomal nanovaccines strongly activate cellular immunity

Cancer immunotherapies, such as immune checkpoint inhibition therapy, have been attracting attention in recent years as new methods for treating cancer.

2 Nov 2022

UC Davis launches new center to accelerate the development of promising cancer therapies

UC Davis Comprehensive Cancer Center has launched a Center for Experimental Therapeutics in Cancer to accelerate promising cancer therapies from the lab to the bedside.

From The University of California, Davis 10 Oct 2022

Research shows readily available pharmaceutical manufacturing capacity in the United States

President Joe Biden signed an executive order Sept. 12 to launch a National Biotechnology and Biomanufacturing Initiative, noting the United States relies too heavily on foreign materials and foreign bioproduction.

5 Oct 2022

MD Anderson and Virogin Biotech collaborate to advance the development of investigational oncolytic viruses, treatments

The University of Texas MD Anderson Cancer Center and Virogin Biotech today announced a strategic collaboration to accelerate the development of investigational treatments, including oncolytic viruses and immunotherapies, for patients with advanced cancers.

12 Sep 2022

Yeast platform for the production of plant-derived anti-cancer drug

The supply of a plant-derived anti-cancer drug can finally meet global demand after a team of scientists from Denmark and the U.S. engineered yeast to produce the precursor molecules, which could previously only be obtained in trace concentrations in the native plant.

1 Sep 2022

Therapeutic mRNAs do not significantly impact translational fidelity

Synthetic mRNA therapeutics for the treatment and prevention of disease has attracted a lot of interest due to the exceptional efficacy of mRNA vaccinations against SARS-CoV-2.

30 Aug 2022

Mayo Clinic's strategic collaboration in biomanufacturing focuses on delivering novel biotherapeutics

Mayo Clinic today announced a strategic collaboration in biomanufacturing to deliver novel biotherapeutics for rare and complex conditions.

17 Aug 2022

Extract from the roots of Rhodiola rosea may be effective for managing type 2 diabetes

A team of researchers led by the University of California, Irvine has discovered that treatment with an extract from the roots of the Rhodiola rosea plant might be effective for helping manage type 2 diabetes, showing promise as a safe and effective non-pharmaceutical alternative.

16 Aug 2022

New technique enables researchers to pinpoint protein–drug interaction

The discovery and development of new drugs may be facilitated by the use of a novel method that can analyze the interactions of drug molecules with proteins in tissue samples. In cooperation with the major biopharmaceutical company AstraZeneca, University of Birmingham researchers created the method.

15 Jul 2022

Challenges in Drug Discovery; Where are we now, and where are we going?

As part of our SLAS Europe 2022 coverage, we speak to Steve Rees, Vice-President of Discovery Biology at AstraZeneca, about the challenges currently faced by the drug discovery sector.

From Society for Laboratory Automation and Screening (SLAS) 8 Jul 2022

How can High-Content Screening accelerate Drug Discovery?

As part of our SLAS Europe 2022 coverage, we speak to Professor Jeremy Simpson from the University College Dublin about the role high-content screening can play in accelerating drug discovery.

From Society for Laboratory Automation and Screening (SLAS) 6 Jul 2022

New biomedical research tool may help advance molecular diagnostics and drug discovery

A new biomedical research tool that enables scientists to measure hundreds of functional proteins in a single cell could offer new insights into cell machinery.

30 Jun 2022

Sharks may be key to developing effective COVID-19 treatments

To combat viruses, one of humankind's oldest threats, researchers are studying predators with the oldest adaptive immune system in the animal kingdom: sharks.

1 Jun 2022

Research shows how current drugs impact bacterial physiology

Tuberculosis is a stubborn disease caused by even more stubborn bacteria. While many bacterial infections clear up within days of taking antibiotics, TB can take up to six months to clear up and, in some cases, never leave the human body. In 2020, it claimed 1.5 million lives, second only to COVID-19 in terms of infectious disease deaths.